Fiona Simpson

Brisbane, QLD 4072, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 58 publications

Utilizing biorecognition to prime tumors for enhanced nanomedicine delivery of alpha therapies.

Utilizing biorecognition to prime tumors for enhanced nanomedicine delivery of alpha therapies.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Published: November 21, 2025

Development of a high-affinity anti-ROR1 variable region for broad anti-cancer immunotherapy.

Development of a high-affinity anti-ROR1 variable region for broad anti-cancer immunotherapy.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: January 08, 2025

Steroid Premedication and Monoclonal Antibody Therapy: Should We Reconsider?

Steroid Premedication and Monoclonal Antibody Therapy: Should We Reconsider?

Journal: Current treatment options in oncology

Published: November 30, 2023

Antibody dependent cellular cytotoxicity-inducing anti-EGFR antibodies as effective therapeutic option for cutaneous melanoma resistant to BRAF inhibitors.

Antibody dependent cellular cytotoxicity-inducing anti-EGFR antibodies as effective therapeutic option for cutaneous melanoma resistant to BRAF inhibitors.

Journal: Frontiers in immunology

Published: November 10, 2023

Epidermal growth factor potentiates EGFR(Y992/1173)-mediated therapeutic response of triple negative breast cancer cells to cold atmospheric plasma-activated medium.

Epidermal growth factor potentiates EGFR(Y992/1173)-mediated therapeutic response of triple negative breast cancer cells to cold atmospheric plasma-activated medium.

Journal: Redox biology

Published: October 26, 2023

A PEGylated liposomal formulation of prochlorperazine that limits brain exposure but retains dynamin II activity: A potential adjuvant therapy for cancer patients receiving chemotherapeutic mAbs.

A PEGylated liposomal formulation of prochlorperazine that limits brain exposure but retains dynamin II activity: A potential adjuvant therapy for cancer patients receiving chemotherapeutic mAbs.

Journal: Nanomedicine : nanotechnology, biology, and medicine

Published: September 26, 2023

TGF-β signalling limits effector function capacity of NK cell anti-tumour immunity in human bladder cancer.

TGF-β signalling limits effector function capacity of NK cell anti-tumour immunity in human bladder cancer.

Journal: EBioMedicine

Published: August 29, 2023

Dose-Dependent Effect of Phenothiazines as Dynamin II Inhibitors on the Uptake of PEGylated Liposomes by Endocytic Cells and In Vivo Pharmacokinetics of PEGylated Liposomal Doxorubicin in Rats.

Dose-Dependent Effect of Phenothiazines as Dynamin II Inhibitors on the Uptake of PEGylated Liposomes by Endocytic Cells and In Vivo Pharmacokinetics of PEGylated Liposomal Doxorubicin in Rats.

Journal: Molecular pharmaceutics

Published: August 07, 2023

Development of an in vivo murine model of perineural invasion and spread of cutaneous squamous cell carcinoma of the head and neck.

Development of an in vivo murine model of perineural invasion and spread of cutaneous squamous cell carcinoma of the head and neck.

Journal: Frontiers in oncology

Published: May 30, 2023

Endocytosis in cancer and cancer therapy.

Endocytosis in cancer and cancer therapy.

Journal: Nature reviews. Cancer

Published: April 11, 2023

Overlapping Machinery in Lysosome-Related Organelle Trafficking: A Lesson from Rare Multisystem Disorders.

Overlapping Machinery in Lysosome-Related Organelle Trafficking: A Lesson from Rare Multisystem Disorders.

Journal: Cells

Published: October 04, 2022

Weaponizing natural killer cells for solid cancer immunotherapy.

Weaponizing natural killer cells for solid cancer immunotherapy.

Journal: Trends in cancer

Published: August 01, 2022

Showing 1-12 of 58

Last Updated: 09/26/2026